Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.
Journal article
Passos PRC. et al, (2026), Diabetes Care
Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.
Journal article
Mathara Diddhenipothage SAD. et al, (2026), Clin Endocrinol (Oxf)
Adiposity rebound and height velocity in patients with Congenital Adrenal Hyperplasia.
Journal article
Lawrence NR. et al, (2026), Eur J Endocrinol
Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions.
Journal article
Dong J. et al, (2026), BJOG
Glucocorticoid Prescribing Trends in Congenital Adrenal Hyperplasia, 2017 to 2023.
Journal article
Roxas A. et al, (2026), Endocr Connect
